Company-level financial information

ANI PHARMACEUTICALS INC

Selected annual earnings and cash-flow facts from SEC filings. Each row identifies its exact reporting period and original filing.

Annual net income

Reported annual periods; USD. Negative values extend below the baseline.

Selected annual US-GAAP cash-flow and earnings facts · USD
Reporting period	Measure	USD millions	Filing
Dec 31, 2025From Jan 1, 2025	Operating cash flow	185.2	SEC filingFeb 27, 2026
Dec 31, 2025From Jan 1, 2025	Net income	78.3	SEC filingFeb 27, 2026
Dec 31, 2025From Jan 1, 2025	Total cash dividends	1.2	SEC filingFeb 27, 2026
Dec 31, 2025From Jan 1, 2025	Capital expenditures (PP&E)	13.8	SEC filingFeb 27, 2026
Dec 31, 2024From Jan 1, 2024	Operating cash flow	64.0	SEC filingFeb 27, 2026
Dec 31, 2024From Jan 1, 2024	Net income	-18.5	SEC filingFeb 27, 2026
Dec 31, 2024From Jan 1, 2024	Total cash dividends	1.6	SEC filingFeb 27, 2026
Dec 31, 2024From Jan 1, 2024	Capital expenditures (PP&E)	16.2	SEC filingFeb 27, 2026
Dec 31, 2023From Jan 1, 2023	Operating cash flow	119.0	SEC filingFeb 27, 2026
Dec 31, 2023From Jan 1, 2023	Net income	18.8	SEC filingFeb 27, 2026
Dec 31, 2023From Jan 1, 2023	Total cash dividends	1.6	SEC filingFeb 27, 2026
Dec 31, 2023From Jan 1, 2023	Capital expenditures (PP&E)	8.9	SEC filingFeb 27, 2026
Dec 31, 2022From Jan 1, 2022	Operating cash flow	-31.2	SEC filingFeb 28, 2025
Dec 31, 2022From Jan 1, 2022	Net income	-47.9	SEC filingFeb 28, 2025
Dec 31, 2022From Jan 1, 2022	Total cash dividends	1.6	SEC filingFeb 28, 2025
Dec 31, 2022From Jan 1, 2022	Capital expenditures (PP&E)	8.9	SEC filingFeb 28, 2025
Dec 31, 2021From Jan 1, 2021	Operating cash flow	3.3	SEC filingFeb 29, 2024
Dec 31, 2021From Jan 1, 2021	Net income	-42.6	SEC filingFeb 29, 2024
Dec 31, 2021From Jan 1, 2021	Total cash dividends	0.2	SEC filingFeb 29, 2024
Dec 31, 2021From Jan 1, 2021	Capital expenditures (PP&E)	2.6	SEC filingFeb 29, 2024
Dec 31, 2020From Jan 1, 2020	Operating cash flow	15.3	SEC filingMar 9, 2023
Dec 31, 2020From Jan 1, 2020	Net income	-22.5	SEC filingMar 9, 2023
Dec 31, 2020From Jan 1, 2020	Total cash dividends	0.0	SEC filingMar 15, 2022
Dec 31, 2020From Jan 1, 2020	Capital expenditures (PP&E)	6.1	SEC filingMar 9, 2023
Dec 31, 2019From Jan 1, 2019	Operating cash flow	45.6	SEC filingMar 15, 2022
Dec 31, 2019From Jan 1, 2019	Net income	6.1	SEC filingMar 15, 2022
Dec 31, 2019From Jan 1, 2019	Total cash dividends	0.0	SEC filingMar 15, 2022
Dec 31, 2019From Jan 1, 2019	Capital expenditures (PP&E)	6.6	SEC filingMar 15, 2022

Latest filed value per tag and exact annual period, within the last seven years. Common-stock and total cash dividends are separate measures; do not add them together. These selected facts are not a complete financial statement.